Virginia Retirement Systems ET AL Acquires 35,600 Shares of Allergan plc (AGN)

Virginia Retirement Systems ET AL increased its holdings in shares of Allergan plc (NYSE:AGN) by 139.1% during the third quarter, Holdings Channel reports. The fund owned 61,200 shares of the company’s stock after buying an additional 35,600 shares during the period. Virginia Retirement Systems ET AL’s holdings in Allergan were worth $11,657,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Edgewood Management LLC boosted its position in Allergan by 2.6% during the second quarter. Edgewood Management LLC now owns 5,728,391 shares of the company’s stock worth $955,037,000 after acquiring an additional 144,282 shares during the last quarter. Janus Henderson Group PLC boosted its position in Allergan by 16.3% during the second quarter. Janus Henderson Group PLC now owns 4,778,699 shares of the company’s stock worth $796,712,000 after acquiring an additional 668,343 shares during the last quarter. Northern Trust Corp boosted its position in Allergan by 1.7% during the second quarter. Northern Trust Corp now owns 4,163,556 shares of the company’s stock worth $694,149,000 after acquiring an additional 69,651 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Allergan by 2.9% during the second quarter. Bank of New York Mellon Corp now owns 3,545,557 shares of the company’s stock worth $591,116,000 after acquiring an additional 99,490 shares during the last quarter. Finally, Parnassus Investments CA boosted its position in Allergan by 3.1% during the second quarter. Parnassus Investments CA now owns 1,844,804 shares of the company’s stock worth $307,566,000 after acquiring an additional 55,029 shares during the last quarter. Hedge funds and other institutional investors own 77.55% of the company’s stock.

In other Allergan news, Director Joseph H. Boccuzi bought 900 shares of the business’s stock in a transaction that occurred on Thursday, August 30th. The shares were purchased at an average cost of $190.59 per share, with a total value of $171,531.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Christopher J. Coughlin bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 6th. The shares were acquired at an average cost of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. 0.36% of the stock is currently owned by insiders.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Allergan from a “hold” rating to a “buy” rating and set a $197.00 price target on the stock in a research report on Wednesday, July 11th. ValuEngine lowered shares of Allergan from a “hold” rating to a “sell” rating in a report on Wednesday, October 31st. Cantor Fitzgerald set a $180.00 target price on shares of Allergan and gave the company a “hold” rating in a report on Thursday, July 19th. Raymond James decreased their target price on shares of Allergan from $232.00 to $198.00 and set a “buy” rating on the stock in a report on Wednesday, October 31st. Finally, Wells Fargo & Co reiterated a “buy” rating on shares of Allergan in a report on Wednesday, October 31st. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $210.18.

Allergan stock opened at $169.61 on Thursday. The company has a market capitalization of $55.72 billion, a PE ratio of 10.37, a P/E/G ratio of 1.31 and a beta of 1.31. Allergan plc has a 1 year low of $142.81 and a 1 year high of $197.00. The company has a current ratio of 0.92, a quick ratio of 0.78 and a debt-to-equity ratio of 0.32.

Allergan (NYSE:AGN) last released its quarterly earnings results on Tuesday, October 30th. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.04 by $0.21. The business had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.89 billion. Allergan had a net margin of 14.50% and a return on equity of 8.44%. The business’s revenue was down 3.0% on a year-over-year basis. During the same period in the previous year, the firm earned $4.15 EPS. On average, research analysts forecast that Allergan plc will post 16.42 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 14th. Stockholders of record on Tuesday, November 13th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.70%. The ex-dividend date is Friday, November 9th. Allergan’s dividend payout ratio (DPR) is 17.61%.

TRADEMARK VIOLATION WARNING: This article was first reported by WKRB News and is the property of of WKRB News. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.wkrb13.com/2018/11/08/virginia-retirement-systems-et-al-acquires-35600-shares-of-allergan-plc-agn.html.

Allergan Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Recommended Story: What is a Tariff?

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply